Therapeutic effect of a MUC1-specific monoclonal antibody-drug conjugates against pancreatic cancer model
Abstract Background Pancreatic cancer is one of the most aggressive malignancies without effective targeted therapies. MUC1 has emerged as a potential common target for cancer therapy because it is overexpressed in a variety of different cancers including the majority of pancreatic cancer. However,...
Main Authors: | Guang Wu, Lan Li, Mengnan Liu, Chunyan Chen, Guangze Wang, Zewei Jiang, Yaqian Qin, Licai He, Hongzhi Li, Jiawei Cao, Haihua Gu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-12-01
|
Series: | Cancer Cell International |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12935-022-02839-w |
Similar Items
-
Antitumor effect of a novel humanized MUC1 antibody-drug conjugate on triple-negative breast cancer
by: Lan Li, et al.
Published: (2023-04-01) -
Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety
by: Yanming Wang, et al.
Published: (2020-03-01) -
PEG Linker Improves Antitumor Efficacy and Safety of Affibody-Based Drug Conjugates
by: Qiyu Li, et al.
Published: (2021-02-01) -
Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
by: Jakub Radocha, et al.
Published: (2021-03-01) -
Tumor Site-Specific Cleavage Improves the Antitumor Efficacy of Antibody–Drug Conjugates
by: Keyuan Xu, et al.
Published: (2023-07-01)